13 results
8-K
EX-99.2
ALKS
Alkermes plc
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
16.0 (2.83) Weekly Cataplexy Rate, mean (SD) 9.0 (10.61) NT1 Patients Demographic Characteristic Total (N=4) Age, years, mean (SD) 23.5 (6.40) Female, n
8-K
EX-99.2
ALKS
Alkermes plc
23 Oct 23
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
8:27am
) NT1 Patients Demographic Characteristic Total (N=4) Age, years, mean (SD) 23.5 (6.40) Female, n (%) 1 (25) White Race, n (%) 4 (100) Body Mass Index
DEFC14A
ALKS
Alkermes plc
25 May 23
Proxy in contested solicitation
4:03pm
White
Did not disclose demographic background
ALKERMES PLC 2023 Proxy Statement 37
Table of Contents
Board Skills Matrix
The following table
PRER14A
u4ej6 2xvn
19 May 23
Preliminary revised proxy
5:23pm
PREC14A
iv4hxfwip
8 May 23
Preliminary proxy with contested solicitation
4:34pm
DEFC14A
5pvbjl3 r5u
6 Jun 22
Proxy in contested solicitation
5:29pm
PREC14A
alk00qs
26 May 22
Preliminary proxy with contested solicitation
5:29pm
424B3
4ottvr2g8jlgnp 0q
5 Aug 11
Prospectus supplement
12:00am
S-4/A
56ck2b a31lq2waicf
2 Aug 11
Registration of securities issued in business combination transactions (amended)
12:00am
S-4
w0y9o4m6cjptd5e3ks1
23 Jun 11
Registration of securities issued in business combination transactions
12:00am
- Prev
- 1
- Next